Literature DB >> 24683831

[Alpha-2 adrenoreceptor agonists in anaesthesia and intensive care medicine].

G Mavropoulos, G Minguet, J F Brichant.   

Abstract

Alpha-2 adrenoreceptor agonists have long been used in the treatment of arterial hypertension. However, in that indication they have progressively been replaced by antihypertensive drugs with a more interesting therapeutic profile. Nonetheless, pharmacological activation of alpha-2 adrenoreceptors leads to a variety of clinical effects that are of major interest for anaesthesia and intensive care practice. Indeed, the sedative and analgesic properties of alpha-2 adrenoreceptor agonists allow a reduction of hypnotic and opioid needs during general anaesthesia. In addition, they induce a down-regulation of the level of consciousness comparable to that of natural slow-wave sleep during post-anaesthesia and intensive care unit stay. These drugs may also prevent some deleterious effects of the sympathetic discharge in response to surgical stress. Furthermore, alpha-2 adrenoreceptor agonists are potent adjuncts for locoregional anaesthesia. In this article, we will summarize the most frequent applications of alpha-2 adrenoreceptor agonists in anaesthesia and intensive care medicine. We will focus on the clinical data available for the two most representative molecules of this pharmacological class: clonidine and dexmedetomidine.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24683831

Source DB:  PubMed          Journal:  Rev Med Liege        ISSN: 0370-629X


  2 in total

1.  Combined use of intrathecal opioids and dexmedetomidine in the management of neuropathic pain.

Authors:  Mohamed Amin Ghobadifar; Farideh Pourghashdar; Armin Akbarzadeh; Zahra Mosallanejad
Journal:  Korean J Pain       Date:  2015-04-01

Review 2.  Mechanisms of Dexmedetomidine in Neuropathic Pain.

Authors:  Yang Zhao; Jianshuai He; Ning Yu; Changxin Jia; Shilei Wang
Journal:  Front Neurosci       Date:  2020-05-05       Impact factor: 4.677

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.